Compare Lennar Corporation (LEN) vs Pfizer Inc (PFE) Price & Performance

Lennar (LEN) trades at $88.18, up 3.96% in the last session, with a bullish technical signal and support at $86. The stock shows mixed fundamentals: revenue declined to $34.19B in 2025, net income fell to $2.08B, and recent EPS misses occurred, but valuation ratios like P/E of 13.82 and P/B of 0.98 suggest potential undervaluation. A dividend of $0.50 is scheduled for July 2026, while cash flow turned negative in 2025 but is projected to recover in 2026.

Outlook is cautious; analyst consensus is a 'Buy' with a $84.30 price target, but risks include housing affordability pressures and earnings volatility. Upside hinges on execution amid high mortgage rates, with institutional interest noted from CalPERS' recent share acquisition.

Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.

Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.